| Dr Christopher J Munoz, PHARMD | |
|
1327 El Prado Ave, Torrance, CA 90501-2716 | |
| (310) 328-7244 | |
| Not Available |
| Full Name | Dr Christopher J Munoz |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1327 El Prado Ave, Torrance, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609596220 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 69405 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher J Munoz, PHARMD 4597 Larwin Ave, Cypress, CA 90630-3508 Ph: (702) 625-1701 | Dr Christopher J Munoz, PHARMD 1327 El Prado Ave, Torrance, CA 90501-2716 Ph: (310) 328-7244 |
News Archive
Opioid use disorder and overdose deaths are a major public health crisis in the United States. While medication-assisted treatments for opioid use disorder exist, these treatments remain inadequate for many patients, resulting in a high rate of relapse following detoxification.
An international consortium of epidemilogists - including Dr. Alexandra Nieters and Professor Nikolaus Becker of the Clinical Epidemiology Division of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) - has conducted the first ever investigation of genetic factors in the development of non-Hodgkin's lymphoma (NHL) in a study called InterLymph.
Santarus, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the review of the New Drug Application (NDA) for UCERIS (budesonide) tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis from October 16, 2012 to January 16, 2013.
Many patients who regularly take aspirin to thin their blood prior to undergoing coronary artery bypass surgery, have in the past been told to stop the aspirin a week before the operation, but new research has found that they may be better off taking it.
The results of a new study revealed that treatment for women with HER2-positive breast cancer – an aggressive form of the disease which is diagnosed in 10,000 British women each year – slowed the progression of tumors by 40 per cent compared with conventional drugs. Tests on 137 women showed that the new therapy – called T-DM1 – which combines the drug Herceptin with an antibody drug, instead of with standard chemotherapy, appeared to stop the cancer "in its tracks".
› Verified 6 days ago
Dr. Helen Haekyong Whang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3860 Sepulveda Blvd, Torrance, CA 90505 Phone: 310-373-5884 Fax: 310-373-9263 | |
Flora Amy Lee, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4101 Torrance Blvd, Torrance, CA 90503 Phone: 310-540-7676 | |
Christine Gobran, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2900 Lomita Blvd, Torrance, CA 90505 Phone: 310-784-8713 | |
Dr. Ahmed Sadek Atallah, PHD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1327 El Prado Ave, Torrance, CA 90501 Phone: 310-328-7244 Fax: 310-782-3519 | |
Young Yoon Sung, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2800 Plaza Del Amo Unit 14, #14, Torrance, CA 90503 Phone: 310-619-4269 | |
Kristin Anne Dionisio Ignacio, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3640 Lomita Blvd Ste 106, Torrance, CA 90505 Phone: 310-784-8713 | |
Gordana Cutovic, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23600 Telo Ave Ste 150, Torrance, CA 90505 Phone: 424-250-1701 |